Delcath Systems Stock Surges 27% As Q3 Profit Jumps

Delcath Systems (DCTH) reported Q3 2026 revenue of $35.1M, up 71% YoY, driven by HEPZATO KIT sales. CEO Gerard Michel cited therapy adoption, physician demand, and expanded capacity as growth drivers. The company raised full-year revenue guidance to $115M-$117M. Q4 guidance implies a step-down due to holiday impact, with new patient starts expected to slow. The Phase II colorectal cancer trial interim analysis is now expected in Q2 or Q3 2027.

Edesa Biotech (EDSA) and Delcath Systems (DCTH) shares rose 30% after signing a licensing deal and reporting strong Q3 results, respectively. Immunovant (IMVT) and Vir Biotechnology (VIR) shares gained 13% and 14% following positive clinical trial data. EDSA received $12M upfront, DCTH raised FY26 revenue outlook, IMVT met primary endpoint, and VIR showed undetectable HDV RNA in 28 patients.

Delcath (DCTH) reported Q3 2026 revenue of $35.1M, up 71% YoY, driven by HEPZATO KIT adoption. The company added new treatment centers, including AdventHealth, and expects 36 centers by year-end. Clinical trials are progressing, with a Phase II colorectal trial on track for interim analysis in mid-2027. Full-year revenue guidance was raised to $115M-$117M, with Q4 expected to grow 25%-34% YoY.

Delcath Systems (DCTH) reported Q3 2026 revenue of $35.1M, up 70% YoY, driven by higher sales of its liver cancer treatment products. The company raised its full-year revenue guidance to $115M–$117M. Net income increased to $7.0M, and gross margin improved to 89%. HEPZATO KIT revenue grew 69% to $32.7M, while European CHEMOSAT revenue rose to $2.4M. Adjusted EBITDA increased to $11.5M, and operating cash flow reached $8.2M. Delcath also advanced its clinical development programs.

Delcath Systems (DCTH) raised its 2026 revenue guidance to $115M-$117M, projecting HEPZATO KIT volume growth of at least 41% over 2025. Q4 revenue is expected to be $25.8M-$27.8M, down sequentially but up 25%-34% year-over-year, due to holiday scheduling. Growth is attributed to increased use of HEPZATO, patient awareness, and expanded capacity at centers like MD Anderson and Mass General.

Delcath Systems reported Q3 2026 revenue of $35.1M, up 70.7% YoY, and net income of $6.95M, up 737.6% YoY. Growth was driven by increased demand for HEPZATO KIT and commercial expansion. Operating expenses rose due to higher R&D and commercial spending. The company also began a Phase 2 trial for HEPZATO in metastatic breast cancer.